109 reports of this reaction
3.5% of all SODIUM POLYSTYRENE SULFONATE reports
#1 most reported adverse reaction
HYPERKALAEMIA is the #1 most commonly reported adverse reaction for SODIUM POLYSTYRENE SULFONATE, manufactured by ANI Pharmaceuticals, Inc.. There are 109 FDA adverse event reports linking SODIUM POLYSTYRENE SULFONATE to HYPERKALAEMIA. This represents approximately 3.5% of all 3,148 adverse event reports for this drug.
Patients taking SODIUM POLYSTYRENE SULFONATE who experience hyperkalaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERKALAEMIA is moderately reported among SODIUM POLYSTYRENE SULFONATE users, representing a notable but not dominant share of adverse events.
In addition to hyperkalaemia, the following adverse reactions have been reported for SODIUM POLYSTYRENE SULFONATE:
The following drugs have also been linked to hyperkalaemia in FDA adverse event reports:
HYPERKALAEMIA has been reported as an adverse event in 109 FDA reports for SODIUM POLYSTYRENE SULFONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERKALAEMIA accounts for approximately 3.5% of all adverse event reports for SODIUM POLYSTYRENE SULFONATE, making it one of the most commonly reported side effect.
If you experience hyperkalaemia while taking SODIUM POLYSTYRENE SULFONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.